Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
Autore:
Muller, J; Wallukat, G; Dandel, M; Bieda, H; Brandes, K; Spiegelsberger, S; Nissen, E; Kunze, R; Hetzer, R;
Indirizzi:
German Heart Inst, D-13353 Berlin, Germany German Heart Inst Berlin Germany D-13353 t Inst, D-13353 Berlin, Germany Max Delbruck Ctr Mol Med, Berlin, Germany Max Delbruck Ctr Mol Med Berlin Germany ck Ctr Mol Med, Berlin, Germany Immunbiol Forsch GMBH, IMTOX, Berlin, Germany Immunbiol Forsch GMBH Berlin Germany orsch GMBH, IMTOX, Berlin, Germany
Titolo Testata:
CIRCULATION
fascicolo: 4, volume: 101, anno: 2000,
pagine: 385 - 391
SICI:
0009-7322(20000201)101:4<385:IAIPWI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
END-SYSTOLIC STRESS; HEART-FAILURE; EXTRACORPOREAL IMMUNOADSORPTION; BETA-ADRENOCEPTORS; AUTOANTIBODIES; ANTIBODIES; ECHOCARDIOGRAPHY; BETA(1)-ADRENOCEPTOR; AUTOIMMUNITY; BLOCKERS;
Keywords:
dilated cardiomyopathy; autoantibodies;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Muller, J German Heart Inst, Augustenburger Pl 1, D-13353 Berlin, Germany German Heart Inst Augustenburger Pl 1 Berlin Germany D-13353 ny
Citazione:
J. Muller et al., "Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy", CIRCULATION, 101(4), 2000, pp. 385-391

Abstract

Background-Idiopathic dilated cardiomyopathy (IDC) frequently is a progressive disease without causative therapy options. Following the hypothesis that in certain patients autoantibodies against cardiac structures may induce, maintain, or promote the progression of the disease, we investigated whether the elimination of these autoantibodies through immunoadsorption would improve cardiac function. Methods and Results-This prospective case-control study included 34 patients with IDC. Each patient presented with moderate to severe heart failure and evidence of autoantibodies directed against beta(1)-adrenoceptors (beta(1)-AABs), Seventeen patients received standard medical therapy (control group), whereas 17 were also treated with immunoadsorption (treatment group) to eliminate beta(1)-AABs. A 1-year follow-up included echocardiographic assessment of left ventricular ejection fraction and internal diameters, beta(1)-AAB levels, and clinical status every 3 months. Within 1 year, the mean /- SD left ventricular ejection fraction rose from 22.3 +/- 3.3% to 37.9 +/- 7.9% (P = 0.0001) in the treatment group, with a relative increase of 69.9%, However, in the control group, no overall increase was seen (from 23.8+/- 3.0% to 25.2 +/- 5.9%, P = 0.3154). Left ventricular diameter in diastole decreased by 14.5% from 74.5 +/- 7.1 to 63.7 +/- 6.0 mm in the treatment group (P = 0.0001) and by 3.8% (P = 0.2342) in the control group. In the treatment group, the NYHA functional rating improved after immunoadsorption(P = 0.0001). beta(1)-AABs did not increase anew. Conclusions-In IDC, the use of immunoadsorption is superior to the use of standard medical therapy. It significantly improves cardiac performance andclinical status.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 00:25:25